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Purpose of the study
Tenofovir disoproxil fumarate (TDF) is not approved for
use in HIV-infected children (<18 years). In clinical prac-
tice a TAMs-sparing regimen may be needed. Use of TDF
in children seems to be associated with decrease in bone
mineral density that sometimes can stabilize after 24
weeks. The primary purpose was to characterized the
change in bone mineral density (BMD), as measured by
osteosonography (QUS), during and after treatment with
tenofovir-containing HAART.
Methods
We enrolled all HIV-infected children (6–18 years), who
required a change in therapy. They received TDF (children
aged 2–8 years, 8 mg/kg once daily; children aged >8
years, median dose of 210 mg/m2 once daily, maximum
dose of 300 mg once daily) as part of HAART, and were
longitudinally observed during a follow-up of 62 months.
QUS were measured at five follow-up steps: 12, 25, 35, 46,
62 months. At every step at least two patients had BMD
measurements.
Summary of results
We evaluated eight perinatally HIV-infected patients
(mean age 11.3 years ± 4.1. 6 males). All subjects, except
one, had extensive antiretroviral treatment exposure
(mean time 116.1 ± 51.5 months). Not all the patients
were evaluated about the BMD annually, but everybody
had at least two measurements. At baseline (median time
before TDF treatment 9 months), the median ADSoS Z-
score was -0.39 (SD 0.75) and the BTT Z-score was -0.12
(SD 0.61). In our patients, ADSoS and BTT Z-score values,
observed during all the follow-up period, did not show
significant statistical differences from the baseline values
(t-student, 2-tails). At week 62, mean AD-SoS z-score and
BTT Z-score were -0.12 and 1.37, respectively. Response to
therapy was good: five patients maintained their same
therapy with a median increase in absolute CD4 T-cell of
+98 cells/mm3 and an undetectable viral load; the other
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three patients, except one, changed their HAART, main-
taining TDF, and obtain an undetectable viral load. No
patients presented renal toxicity or any other clinically sig-
nificant adverse events correlated to TDF. See Figures 1
and 2.
Conclusion
Our young patients do not seem to be at greater risk for
bone toxicity. And a non-invasive technique, such as QUS
technology, opens up new interesting perspectives, allow-
ing following of bone mass changes in vertically infected
patients and better multiple evaluation of the role of dis-
ease-related conditions or treatments able to interfere
with bone mass acquisition during growth.
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